Detection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent.
A new hepatobiliary contrast agent (Mn-DPDP) was used in the detection of liver metastases in six rabbits with seven hepatic V2 carcinomas. This contrast agent is derived from pyridoxyl-5-phosphate which is biomimetically designed to be secreted by the hepatocyte. After Mn-DPDP administration, a 105% increase in liver signal to noise was obtained using a 200/20 (TR/TE) pulsing sequence, and a 62% decrease in intensity was observed using a 1200/60 pulsing sequence. Liver V2 carcinoma contrast enhancement increased 427% using the 200/20 pulsing sequence and 176% using the 1200/60 pulsing sequence. Four of seven V2 carcinomas were not detectable prior to the administration of Mn-DPDP (50 mumol/kg). Two neoplasms were only detectable in retrospect (after Mn-DPDP) on the 1200/60 sequence. The smallest neoplasms detected in this study were 1-4 mm. Mn-DPDP appears to be a promising MRI contrast agent.
Young
S W
SW
Department of Diagnostic Radiology, Stanford University School of Medicine, CA 94305.
Bradley
B
B
Muller
H H
HH
Rubin
D L
DL
D000818:Animals; D002277:Carcinoma / Q000175:diagnosis* / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D004492:Edetic Acid / Q000031:analogs & derivatives; D007089:Image Enhancement / Q000379:methods*; D008114:Liver Neoplasms, Experimental / Q000175:diagnosis* / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*; D011817:Rabbits; D013997:Time Factors
D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid